IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 325 filers reported holding IONIS PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.84 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $46,875,235 | +1.2% | 1,033,404 | -8.5% | 0.01% | 0.0% |
| Q2 2023 | $46,318,275 | +29.2% | 1,128,888 | +12.6% | 0.01% | +25.0% |
| Q1 2023 | $35,847,541 | +1.3% | 1,003,009 | +7.1% | 0.00% | 0.0% |
| Q4 2022 | $35,379,499 | +14.8% | 936,709 | +34.5% | 0.00% | 0.0% |
| Q3 2022 | $30,809,000 | +12.8% | 696,538 | -5.6% | 0.00% | 0.0% |
| Q2 2022 | $27,321,000 | +42.0% | 737,977 | +42.1% | 0.00% | +33.3% |
| Q1 2022 | $19,241,000 | +36.0% | 519,477 | +11.7% | 0.00% | +50.0% |
| Q4 2021 | $14,146,000 | -15.3% | 464,885 | -6.6% | 0.00% | 0.0% |
| Q3 2021 | $16,701,000 | -20.6% | 497,936 | -5.6% | 0.00% | -33.3% |
| Q2 2021 | $21,046,000 | -17.5% | 527,609 | -7.1% | 0.00% | -25.0% |
| Q1 2021 | $25,522,000 | +6.7% | 567,667 | +34.2% | 0.00% | 0.0% |
| Q4 2020 | $23,923,000 | +162.5% | 423,135 | +120.3% | 0.00% | +100.0% |
| Q3 2020 | $9,114,000 | -32.3% | 192,088 | -15.9% | 0.00% | -33.3% |
| Q2 2020 | $13,472,000 | +40.5% | 228,486 | +12.7% | 0.00% | 0.0% |
| Q1 2020 | $9,587,000 | -35.9% | 202,748 | -18.2% | 0.00% | 0.0% |
| Q4 2019 | $14,965,000 | +12.3% | 247,732 | +11.4% | 0.00% | -25.0% |
| Q3 2019 | $13,324,000 | -38.3% | 222,393 | -33.8% | 0.00% | -33.3% |
| Q2 2019 | $21,586,000 | -31.3% | 335,870 | -13.2% | 0.01% | -33.3% |
| Q1 2019 | $31,412,000 | -7.8% | 387,002 | -38.6% | 0.01% | -10.0% |
| Q4 2018 | $34,059,000 | +330.3% | 630,008 | +310.6% | 0.01% | +400.0% |
| Q3 2018 | $7,915,000 | -32.8% | 153,448 | -45.7% | 0.00% | -33.3% |
| Q2 2018 | $11,776,000 | +57.2% | 282,633 | +66.3% | 0.00% | +50.0% |
| Q1 2018 | $7,491,000 | -22.4% | 169,946 | -11.5% | 0.00% | -33.3% |
| Q4 2017 | $9,655,000 | -6.1% | 191,934 | -5.3% | 0.00% | 0.0% |
| Q3 2017 | $10,278,000 | -24.7% | 202,753 | -24.5% | 0.00% | -25.0% |
| Q2 2017 | $13,654,000 | +16.3% | 268,422 | -8.1% | 0.00% | +100.0% |
| Q1 2017 | $11,738,000 | -34.1% | 291,984 | -21.6% | 0.00% | -33.3% |
| Q4 2016 | $17,820,000 | +189.5% | 372,608 | +121.8% | 0.00% | +50.0% |
| Q3 2016 | $6,156,000 | -47.6% | 167,987 | -66.7% | 0.00% | -50.0% |
| Q2 2016 | $11,759,000 | +162.0% | 504,861 | +355.6% | 0.00% | +100.0% |
| Q1 2016 | $4,488,000 | -59.3% | 110,810 | -37.7% | 0.00% | -50.0% |
| Q4 2015 | $11,017,000 | – | 177,910 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tweedy, Browne Co LLC | 3,541,136 | $133,749 | 7.12% |
| Bellevue Group AG | 9,743,900 | $368,027,103 | 4.88% |
| M28 Capital Management LP | 126,300 | $4,770,351 | 4.55% |
| Sicart Associates LLC | 246,258 | $9,301,165 | 3.28% |
| Camber Capital Management LP | 1,925,000 | $72,707 | 2.49% |
| Privium Fund Management B.V. | 148,807 | $5,557,941 | 2.11% |
| Deep Track Capital, LP | 1,205,773 | $45,542,046 | 1.91% |
| BVF INC/IL | 1,121,809 | $42,370,726 | 1.79% |
| Orbimed Advisors | 1,993,600 | $75,298,272 | 1.44% |
| Parkman Healthcare Partners LLC | 141,115 | $5,329,914 | 1.42% |